Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone

International Clinical Psychopharmacology

Volumn 20, Issue 3, 2005, Pages 173-176

  Pae, Chi Un ^a   Lim, Hyun Kook ^b   Kim, Tae Suk ^a   Kim, Jung Jin ^a   Lee, Chang Uk ^a   Lee, Soo Jung ^a   Lee, Chul ^a   Paik, In Ho ^a,c  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Chuncheon National Hospital   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Hepatic enzyme; Olanzapine; Retrospective study; Risperidone

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; ATYPICAL ANTIPSYCHOTIC AGENT; LIVER ENZYME; OLANZAPINE; RISPERIDONE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; FEMALE; HUMAN; LIVER FUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RETROSPECTIVE STUDY; REVIEW; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; TREATMENT OUTCOME;

ADULT; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANTIPSYCHOTIC AGENTS; ASPARTATE AMINOTRANSFERASES; BENZODIAZEPINES; FEMALE; HUMANS; INPATIENTS; LIVER; LIVER FUNCTION TESTS; MALE; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA;

EID: 17644400481     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200505000-00009     Document Type: Review

References (17)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press.
2. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S (1996). Olanzapine versus placebo and haloperidol: acute phase results of the North American double blind olanzapine trial. Neuropsychopharmacology 14:111-123.
3. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW (2003). Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28:182-192.
4. Carrillo JA, Herraiz AG, Ramos SI, Gervasini G, Vizcaino S, Benitez J (2003). Role of the smoking-induced cytochrome P450 (CYP) 1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 23:119-127.
5. Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, et al. (2002). Hepatic tolerance of atypical antipsychotic drugs. Encephale 28:542-551.
6. Eli Lilly and Company (2000). Zyprexa (Olanzapine) Prescribing Information. Indianapolis, IN: Eli Lilly and Company.
7. Gonzalez-Heydrich J, Raches D, Wilens TE, Leichtner A, Mezzacappa E (2003). Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. J Am Acad Child Adolesc Psychiatry 42:1227-1233.
8. Hansen TE, Casey DE, Hoffman WF (1986). Neuroleptic intolerance. Schizophr Bull 17:567-582.
9. Hummer M, Kurz M, Kurzthaler I, Oberauer H, Miller C, Fleischhacker WW (1997). Hepatotoxicity of clozapine. J Clin Psyhchopharmacol 17: 314-317.
10. Ines G, Altendorf K, Batra A, Gartner HJ (1999). Relevance of liver enzyme elevations with four different neuroleptics; a retrospective review of 7263 treatment courses. J Clin Psychophamcol 21:215-222.
11. Kaplowits N, Aw TY, Simon FR, Stolz A (1986). Drug induced hepatotoxicity. Ann Intern Med 104:826-839.
12. Kumra S, Herion D, Jacobsen LK, Briguglia C, Grothe D (1997). Case study: risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 36:701-705.
13. Marder SR, Meibach RC (1994). Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835.
14. Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, Gelders Y (1989). Therapeutic effect and safety of increasing doses of risperidone in psychotic patients. Psychopharmacology (Berl) 99:445-449.
15. Physician's Desk Reference (2002). Montvale NJ: Medical Economics Company.
16. Prior TI, Baker GB (2003). Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 28:99-112.
17. Szigethy E, Wiznitzer M, Branicky LA, Maxwell K, Findling RL (1999). Risperidone-induced hepatotoxicity in children and adolescents? A chart review study. J Child Adolesc Psychopharmacol 9:93-98.